• Tubulis
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • moc.silubut@ofni
Tubulis Geschaeftsleitung

Dr. Dominik Schumacher
Dr. Jonas Helma-Smets

About Tubulis

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era. The company was founded in 2019 based on innovation coming out of the LMU Munich and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin. Our growing team of chemists, biologists and executive leaders has since then advanced these technologies developing a new suite of additive technologies proprietary to Tubulis. Our deep scientific understanding of the field puts us in the unique position to build on the discoveries made over the past 20 years in the ADC space and translate this understanding into meaningful therapeutic benefits for patients.

What is your motivation?

At Tubulis, we are driven by our goal of unlocking new avenues for the treatment of solid tumors in order to bring safe, effective therapies to patients living with cancer. Our aim is to deliver the true therapeutic potential of antibody-drug conjugates (ADCs), by accessing novel cancer targets and innovative payloads using our proprietary conjugation techniques. While innovation in the ADC field has come a long way, ADCs still face significant bottlenecks related to toxicity, efficacy and indication. We are well-equipped to address and overcome these hurdles with our platforms, which allow us to go beyond the traditional ADC design. This vision of ushering in a new ADC era capable of delivering improved outcomes for those battling cancer unites and inspires the Tubulis team.

“The ZB provides our team with a valuable infrastructure and network that is conducive to our goal of opening new avenues for the treatment of solid tumors and bringing safe and effective ADCs to patients.”

Dr. Dominik Schumacher
Dr. Jonas Helma-Smets